

Cognitive behavioural therapy for People with Asperger Syndrome and Anxiety disorders

| | | |
|--|---|---|
| Submission date 20/02/2012 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 20/02/2012 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 22/11/2018 | Condition category Mental and Behavioural Disorders | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

This study aims to find out whether or not a psychological treatment, cognitive behaviour therapy (CBT), can help people with Asperger Syndrome (AS) and high functioning autism who have problems with anxiety. AS is often described as a form of high-functioning autism. People with anxiety disorders such as social phobia or specific phobias can be described as being afraid of social situations, or particular situations (e.g., lifts) or objects (e.g., spiders), so much so that a person may avoid going out for social activities or work. They usually experience a sense of dread or fear that something terrible may happen, such as being laughed at or being judged negatively, they may also tremble, sweat, and have panic symptoms. These problems may significantly impair their quality of life. There are many studies showing that CBT can help people with anxiety. Many adults with AS have problems with anxiety but there have been no studies which have tried to find out whether or not CBT can help these people. There have been some completed studies with children with AS showing that CBT can help with anxiety. People with AS tend to have special interests, such as collecting large numbers of items, and have difficulties with social situations. They may have problems with understanding what facial expressions and hand gestures mean, and have difficulties with making friends. It is not surprising that studies have found that people with AS have higher levels of anxiety than people without AS. We want to find out whether or not psychological treatments for anxiety can be adapted and used to successfully treat the anxiety experienced by people with AS.

Who can participate?

Patients aged 16 or over with AS or high functioning autism and clinically significant levels of anxiety from the counties of Norfolk, Kent and Hertfordshire.

What does the study involve?

Participants are randomly allocated into one of two groups. One group receives modified individual and group CBT delivered by trained CBT therapists. The other group is put on a waiting list to receive the CBT later. The CBT involves anxiety management techniques and social skills training. Anxiety is assessed before and after the CBT and at the 6-month follow-up.

What are the possible benefits and risks of participating?

The results of this study may help us to improve satisfaction with the NHS for people with

autistic spectrum disorders who have mental health problems, but do not receive treatment. The study will help to determine whether or not CBT will be effective at improving anxiety amongst adults with AS, and whether it represents good value for money.

Where is the study run from?
University of East Anglia (UK)

When is the study starting and how long is it expected to run for?
August 2011 to August 2012

Who is funding the study?
National Institute of Health Research (NIHR) (UK)

Who is the main contact?
Dr Peter Langdon
p.langdon@uea.ac.uk

Contact information

Type(s)
Scientific

Contact name
Dr Peter Langdon

Contact details
Clinical Senior Lecturer
Department of Psychological Sciences
Norwich Medical School
University of East Anglia
Norwich Research Park
Norwich
United Kingdom
NR4 7TJ
+44 (0)160 359 3599
p.langdon@uea.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
8370

Study information

Scientific Title

Cognitive behavioural therapy for People with Asperger Syndrome and Anxiety disorders: a pilot randomised control trial

Acronym

PAsSA

Study objectives

There is a body of literature demonstrating that children, adolescents and adults with Asperger Syndrome (AS) and high functioning autism have significant problems with anxiety. There is evidence to suggest that cognitive behaviour therapy (CBT) is an effective treatment for anxiety, and there is a growing interest in examining the utility of cognitive behaviour therapy for people with AS who have mental health problems. Currently, there are no known clinical trials in the United Kingdom of cognitive behaviour therapy for anxiety amongst adults with AS, although there are studies examining this in children. There are known methods of modification to therapy for this client group and it is appropriate to undertake a limited trial with adults with AS in the United Kingdom.

The aim is to determine whether or not modified CBT can successfully reduce the symptoms of anxiety experienced by people with AS, and whether or not this intervention is cost effective. We will make use of a single-blind cross-over trial incorporating pre-, post- and follow-up assessment of anxiety. A mixture of clinician ratings and self-ratings of anxiety will be used. The intervention will be modified individual and group CBT delivered by trained CBT therapists, and the assessment of anxiety will be completed by research assistants who will be blind to group allocation.

This study is a randomised single blind cross over trial of CBT for people with AS who have clinically significant levels of anxiety. Thirty five participants who complete the entire trial will be recruited from the counties of Norfolk, Kent and Hertfordshire. However, we may include other counties in the future. Levels of symptomatology will be measured pre- and post-group and at follow-up by research assistants who will be blind to group allocation. This will generate data regarding the effectiveness of this type of psychological intervention with people who have AS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Cambridgeshire 4 NHS Research Ethics Committee, 01/07/2010, ref: 10/H0305/42

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Mental Health Research Network, Primary Care Research Network for England; Subtopic: Anxiety, Autism spectrum disorders, Not Assigned; Disease: Anxiety, Autism spectrum disorders

Interventions

Group CBT, The treatment package utilises techniques delivered in a group based format. These include cognitive restructuring, anxiety management techniques, systematic desensitization, exposure to feared social situations, and social skills training. Cognitive restructuring refers to the process of learning to identify unhelpful cognitions which may trigger or maintain anxiety and then learning to challenge or replace these cognitions with cognitions that are rational. Follow Up Length: 6 month(s); Study Entry : Single Randomisation only

Intervention Type

Behavioural

Primary outcome measure

1. Social Phobia Inventory (Connor et al., 2000)
2. Liebowitz Social Anxiety Scale (Heimberg et al.)

Timepoint(s): Administered on Three Occassions

Measured before the intervention starts, after the intervention is finished, and at six months after the intervention has finished

Secondary outcome measures

1. Resource Use Questionnaire; Timepoint(s): Administered on Three Occassions
2. SF-36 (www.sf-36.org) and EQ-5D (www.euroqol.org) generic health-related quality of life scales.; Timepoint(s): Administered on Three Occassions
3. Social and Emotional Functioning Interview (Informant and Subject Versions; Rutter et al., 1988); Timepoint(s): Administered on Three Occassions
4. Social Interaction Anxiety Scale (Heimberg et al., 1992; Brown et al., 1997), and
5. Fear Questionnaire; Timepoint(s): Administered on Three Occassions

Measured before the intervention starts, after the intervention is finished, and at six months after the intervention has finished

Overall study start date

08/08/2011

Completion date

08/08/2012

Eligibility

Key inclusion criteria

1. Participants must fulfill diagnostic criteria for AS, or high functioning autism (Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)), and have been diagnosed with AS or PDD-NOS by a paediatrician, clinical psychologist or psychiatrist. The features of AS and PDD-NOS include difficulties with social interaction marked by problems with nonverbal behaviour, and peer relationships. They also have problems with social reciprocity, coupled with stereotyped patterns of behaviour and interests that may be repetitive, as well as clinically significant difficulties with occupational and social functioning. People with AS generally do not have language developmental delays or intellectual disabilities. Only participants with a current diagnosis of AS or PDDNOS will be considered for inclusion within the trial. We will make use of the Krug Asperger Disorder Index as an aide to confirming diagnosis.
2. Participants must have clinical significant difficulties with anxiety and fulfill diagnostic criteria for one or more of the following disorders: panic disorder, agoraphobia, social phobia (social anxiety disorder), specific phobias, or generalised anxiety disorder. This will be confirmed through the use of our screening instruments, such as the Hamilton Rating Scale for Anxiety, and an assessment and screening interview.
3. Participants must be aged 16 or over.; Target Gender: Male & Female; Upper Age Limit 65 years ; Lower Age Limit 16 years

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Planned Sample Size: 35; UK Sample Size: 35

Key exclusion criteria

1. If suffering from post-traumatic stress disorder, or anxiety related to substance misuse. The reason for this exclusion is that people suffering from these disorders may require more specialist intervention as a consequence of the aetiology of these disorders (e.g. trauma and addiction)
2. They have other types of severe mental illness such as psychosis
3. They are currently abusing substances such as alcohol or heroin
4. They have an intellectual disability

Date of first enrolment

08/08/2011

Date of final enrolment

08/08/2012

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
University of East Anglia
Norwich
United Kingdom
NR4 7TJ

Sponsor information

Organisation
Norfolk and Waveney Mental Health NHS FT (UK)

Sponsor details
80 St. Stephens Road
Norwich
United Kingdom
NR1 3RE

Sponsor type
Government

ROR
<https://ror.org/03400ft78>

Funder(s)

Funder type
Government

Funder Name
Research for Patient Benefit Programme

Alternative Name(s)
NIHR Research for Patient Benefit Programme, RfPB

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|----------------------------------|----------|--------------|------------|----------------|-----------------|
| Protocol article | protocol | 30/07/2013 | | Yes | No |
| Results article | results | 13/04/2016 | | Yes | No |